Abstract
A human tamoxifen-resistant mammary carcinoma, MaCa 3366/TAM, originating from a sensitive parental xenograft 3366 was successfully established by treatment of tumour-bearing nude mice with 1–50 mg kg–1 tamoxifen for 3 years during routine passaging. Both tumours did not differ significantly in OR- and PR-positivity, however, when compared with the sensitive tumour line, the mean OR content of the TAM-resistant subline is slightly lower. An OR-upregulation following withdrawal of oestradiol treatment was observed in the parental tumours but not in the resistant xenografts. Following long-term treatment with tamoxifen, the histological pattern of the breast carcinoma changed. The more differentiated structures being apparent after treatment with 17β-oestradiol in the original 3366 tumour were not induced in the resistant line. Tamoxifen failed to induce a tumour growth inhibition in comparison to the tamoxifen-sensitive line. The pure anti-oestrogen, ICI 182 780, revealed cross-resistance. Sequence analysis of the hormone-binding domain of the OR of both lines showed no differences, suggesting that either mutations in other regions of the OR are involved in the TAM-resistance phenotype or that mechanisms outside of this protein induced this phenotype. Oestrogen and anti-oestrogen regulate pS2 and cathepsin D expression in 3366 tumours as in the human breast cancer cell line MCF-7. The resistant 3366/TAM tumours have lost this regulation. The established breast cancer xenografts 3366 and 3366/TAM offer the possibility of investigating mechanisms of anti-oestrogen resistance in an in vivo situation. They can be used to test novel approaches to prevent, or to overcome, this resistance in a clinically related manner. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Augereau P, Garcia M, Mattei MG, Cavailles V, Depadova F, Derocq D, Capony F, Ferrara P and Rochefort H (1988) Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF-7 breast cancer cells and mapping on chromosome 11. Mol Endocrinol 2: 186–192
Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA and Nilsson S (1998) Differential response of oestrogen receptor α and oestrogen receptor β to partial oestrogen agonists/antagonists. Mol Pharmacol 54: 105–112
Brzozowski AM, Pike ACW, Dauter Z, Hubbart RE, Bonn T, Engström O, Öhman L, Green GL, Gustafsson JA and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753–758
Clarke R (1996) Human breast cancer cell line xenografts as models of breast cancer – The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 39: 69–86
Denton RR, Koszewski NJ and Notides AC (1992) Oestrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. J Biol Chem 267: 7263–7268
Early Breast Cancer Trial Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339: 1–15, 71–85
Foekens JA, Portengen H, Look MP, van Putten WLJ, Thirion B, Bontenbal M and Klijn JGM (1994) Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217–1223
Gottardis MM and Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term anti-oestrogen administration. Cancer Res 48: 5183–5187
Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P and Chambon P (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320: 134–139
Jensen BL, Skouv J, Lundholt BK and Lykkesfeldt AE (1999) Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. Br J Cancer 79: 386–392
Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR and Dowsett M (1995) Changes in oestrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331–3338
Karnik PS, Julkarni S, Liu XP, Budd T and Bukowski RM (1994) Oestrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54: 349–353
Katzenellenbogen BS, Montano MM, Ekena K, Herman ME and McInerney EM (1997) Anti-oestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44: 23–38
Landel CC, Kushner PJ and Greene GL (1994) The interaction of human oestrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol 8: 1407–1419
Laborda J (1991) 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19: 3998
Larsen SS, Madsen MW, Jensen BL and Lykkesfeldt AE (1997) Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 72: 1129–1136
Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG and Rose DW (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920–2925
Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Lykkesfeldt AE, Madsen MW and Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54: 1587–1595
Lykkesfeldt AE (1996) Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 5: 9–14
Lykkesfeldt AE (1997). Growth regulation of human breast cancer cells by oestrogens and anti-oestrogens,
Maalouf GJ, Xu W, Smith TF and Mohr SC (1998) Homology model for the ligand-binding domain of the human estrogen receptor. J Biomol Struct Dyn 15: 841–851
Madsen MW, Lykkesfeldt AE, Laursen I, Nielsen KV and Briand P (1992) Altered gene expression of c-myc, epidermal growth factor receptor, transforming growth factor-alpha, and c-erb-B2 in an immortalized human breast epithelial cell line, HMT-3522, is associated with decreased growth factor requirements. Cancer Res 52: 1210–1217
Madsen MW, Reiter BE, Larson SS, Briand P and Lykkesfeldt AE (1997) Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585–589
Mahfoudi A, Roulet E, Dauvois S, Parker MG and Wahli W (1995) Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92: 4206–4210
Martin MB, Saceda M, Garcia-Morales P and Gottardis MM (1994) Regulation of estrogen receptor expression. Breast Cancer Res Treat 31: 183–189
Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A and Chambon P (1982) Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895–7903
Montano MM, Muller V, Trobaugh A and Katzenellenbogen BS (1995) The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9: 814–825
Montella M, Biondi E, deMarco M, Cerra M, Cecco L, Botti G, Bonelli P and Tuccillo F (1996) Breast cancer estrogen and progesterone receptors: a multivariate analysis of associations with clinical and histologic characteristics in a series of 2933 consecutive cases. International Journal of Oncology 9: 977–982
Murphy CS, Langan-Fahey SM, McCague R and Jordan VC (1990) Structure–function relationship of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vivo. Mol Pharmacol 38: 737–743
Murphy LC, Wang M, Coutt A and Dotzlaw H (1996) Novel mutations in the estrogen receptor messenger RNA in human breast cancers. J Clin Endocrinol Metab 81: 1420–1427
Naundorf H and Arnold W (1981) Breeding of nude mice under improved conditions. Zeitschrift fur Versuchstierkunde 23: 77–79
Naundorf H, Fichtner I, Büttner B and Frege J (1992) Establishment and characterization of a new human oestradiol – and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice. J Cancer Res Clin Oncol 119: 35–40
Noguchi S, Motomura K, Inaji H, Imaoka S and Koyama H (1993) Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71: 1266–1272
Osborne CK, Coronado EB and Robinson JP (1987) Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. European Journal of Cancer and Clinical Oncology 23: 1189–1196
Osborne CK and Fuqua SAW (1994) Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32: 49–55
Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ and Scanlan TS (1997) Differential ligand activation of oestrogen receptors ERα and ERβ at AP1 sites. Science 277: 1508–1510
Pink JJ and Jordan VC (1996) Models of estrogen receptor regulation by oestrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321–2330
Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R and Chambon P (1987) Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84: 9243–9247
Thompson EW, Brünner N, Torri J, Johnson MD, Boulay V, Wright A, Lippman ME, Steeg PS and Clarke R (1993) The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 11: 15–26
Tonetti DA and Jordan VC (1995) Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 6: 498–507
Tonetti DA and Jordan VC (1997) The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem Mol Biol 62: 119–128
van Agthoven T, van Agthoven TLA, Dekker A, van der Spek PJ, Vreede L and Dorssers LCJ (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17: 2799–2808
Westley B and Rochefort H (1980) A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353–362
Westley B, May FEB, Brown AMC, Krust A, Chambon P, Lippman ME and Rochefort H (1984) Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF-7 cells and two tamoxifen resistant sublines. J Biol Chem 259: 10030–10035
Wolf DM and Jordan VC (1994) Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 31: 117–127
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Naundorf, H., Becker, M., Lykkesfeldt, A. et al. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Br J Cancer 82, 1844–1850 (2000). https://doi.org/10.1054/bjoc.2000.1156
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1156
Keywords
This article is cited by
-
Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts
Hormones and Cancer (2017)
-
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
BMC Cancer (2016)
-
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity
Clinical & Experimental Metastasis (2008)
-
The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
Targeted Oncology (2007)
-
Tamoxifen-resistant breast carcinoma xenograft
Breast Cancer Research (2000)
